News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
12,517 Results
Type
Article (712)
Company Profile (16)
Press Release (11789)
Section
Business (4452)
Career Advice (15)
Deals (650)
Drug Delivery (2)
Drug Development (2322)
Employer Resources (2)
FDA (197)
Job Trends (263)
News (7154)
Policy (378)
Tag
Academia (37)
Africa (14)
Alliances (1196)
Alzheimer's disease (10)
Antibody-drug conjugate (ADC) (4)
Approvals (196)
Artificial intelligence (1)
Asia (1035)
Australia (88)
Bankruptcy (3)
Best Places to Work (209)
BIOSECURE Act (3)
Biotechnology (14)
C2C Services and Suppliers (296)
California (93)
Canada (27)
Cancer (15)
Career advice (10)
CAR-T (4)
Cell therapy (14)
China (9)
Clinical research (1705)
Collaboration (8)
Colorado (2)
Compensation (3)
COVID-19 (100)
CRISPR (3)
Cystic fibrosis (1)
Data (7)
Delaware (2)
Diabetes (2)
Diagnostics (28)
Drug discovery (1)
Earnings (1335)
Employer resources (2)
Europe (1224)
Events (2274)
Executive appointments (8)
FDA (204)
Florida (6)
Funding (7)
Gene editing (4)
Gene therapy (7)
GLP-1 (16)
Government (42)
Healthcare (383)
Hotbed/Location (9397)
Infectious disease (101)
Inflammatory bowel disease (6)
Intellectual property (2)
Interviews (3)
IPO (352)
Job creations (61)
Job search strategy (10)
Layoffs (8)
Legal (62)
Lung cancer (2)
Lymphoma (2)
Manufacturing (3)
Maryland (37)
Massachusetts (33)
Medical device (62)
Medtech (62)
Mergers & acquisitions (304)
Metabolic disorders (3)
Minnesota (3)
Neuroscience (10)
New Jersey (7)
New York (7)
NextGen Class of 2024 (137)
Non-profit (19)
North Carolina (11)
Northern California (37)
Obesity (1)
Opinion (2)
Pain (1)
Patents (5)
Patient recruitment (1)
Pennsylvania (14)
People (1608)
Phase I (763)
Phase II (842)
Phase III (505)
Pipeline (3)
Policy (5)
Postmarket research (25)
Preclinical (252)
Real estate (111)
Regulatory (288)
Research institute (61)
Resumes & cover letters (3)
Series A (5)
South America (9)
Southern California (29)
Startups (105)
Texas (3)
United States (226)
Vaccines (11)
Washington D.C. (2)
Washington State (7)
Date
Today (8)
Last 7 days (27)
Last 30 days (72)
Last 365 days (1096)
2024 (767)
2023 (1261)
2022 (1595)
2021 (1626)
2020 (1242)
2019 (732)
2018 (540)
2017 (662)
2016 (547)
2015 (591)
2014 (397)
2013 (339)
2012 (292)
2011 (296)
2010 (310)
12,517 Results for "epimab biotherapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
EpimAb Biotherapeutics and Vignette Bio Announce Strategic Collaboration to Develop EMB-06, a BCMA×CD3 Bispecific Antibody
September 4, 2024
·
3 min read
EpimAb Biotherapeutics to Present Late-breaking Abstract on Preclinical Results of EMB-07 at the 2024 American Association for Cancer Research Annual Meeting
EpimAb Biotherapeutics is pleased to announce the acceptance of a late-breaking abstract featuring our novel T-cell engager (TCE) EMB-07 as a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, California between April 5-10, 2024.
March 5, 2024
·
2 min read
EpimAb Biotherapeutics and Almirall Announce Bispecific Antibody License Agreement
EpimAb Biotherapeutics and Almirall announced a license agreement on the development of bispecific antibodies for up to three undisclosed target pairs.
October 12, 2023
·
3 min read
EpimAb Biotherapeutics to Present a Late-Breaking Abstract of First-in-Human Data of EMB-06 at 2023 SITC Annual Meeting
EpimAb Biotherapeutics is excited to announce that the company will present the first-in-human results for EMB-06 in a late-breaking poster presentation at the 2023 Society for Immunotherapy of Cancer Annual Meeting to be held in San Diego, California, from November 3-5.
October 31, 2023
·
2 min read
EpimAb Biotherapeutics to Present Initial First-in-human Data of EMB-02 at the 2023 ESMO Conference
EpimAb Biotherapeutics, a clinical stage biotechnology company specializing in the development of bispecific antibodies, is pleased to announce that the company will present the first-in-human results for EMB-02 as a poster display at the 2023 European Society for Medical Oncology (ESMO) Congress on October 23 (local time).
September 19, 2023
·
2 min read
Business
EpimAb Biotherapeutics Appoints Yonghong Zhu, M.D., Ph.D., as Chief Medical Officer
EpimAb Biotherapeutics, a clinical stage biotechnology company specializing in the development of bispecific antibodies, announced the appointment of Yonghong Zhu, M.D., Ph.D., as Chief Medical Officer.
June 7, 2023
·
2 min read
SAb Biotherapeutics Rebrands as SAB BIO
SAB Biotherapeutics today announced its new name, SAB BIO, and visual identity to more closely align with its mission to treat and prevent immune and autoimmune disorders with the use of its unique immunotherapy platform.
June 20, 2024
·
5 min read
BioMidwest
Adolore BioTherapeutics to Present at the Virtual Investor Pitch Conference
Adolore BioTherapeutics, a biotechnology company focused on developing breakthrough opioid-free gene therapy treatments for chronic pain, announced that it will present at the Virtual Investor Pitch Conference on June 17, 2024 at 10:00 AM ET.
June 10, 2024
·
1 min read
SAB Biotherapeutics Announces Departure of Chief Financial Officer
SAB Biotherapeutics today announced that effective June 4, its Chief Financial Officer Michael King will be departing the company to accept a role as CEO at a privately-held oncology company.
May 30, 2024
·
4 min read
Business
Iovance Biotherapeutics to Present at Upcoming Conferences
September 3, 2024
·
6 min read
1 of 1,252
Next
